Medical Devices Startups

REVA Medical develops bioresorbable polymers for medical implants, with a focus on vascular applications. The company creates drug-eluting bioresorbable scaffolds for treating coronary artery disease, positioned as an alternative to permanent metallic stents.

1 investor

Revamp Medical develops Doraya, a flow-reducing central venous catheter deployed in the infrarenal IVC to improve the efficacy of diuretic therapy in patients with acute heart failure. The device helps cardiologists temporarily manage venous hemodynamics, central venous pressure, and renal afterload to reduce hospital stays and readmissions.

1 investor

Revascular Bio develops cell therapy treatments using vascular endothelial stem cells to address diseases caused by vascular dysfunction, including chronic wounds, severe limb ischemia, and genetic blood disorders. The company targets intractable diseases with angiogenic therapy, angiocrine therapy, and protein production platforms.

1 investor

Revealix is a clinical decision support platform for diabetic foot health risk assessment that enables healthcare providers to screen, document, and stratify patient risk in a 3-minute mobile workflow. The platform is designed to help intercept foot wound risk in primary care settings before wounds develop, addressing preventable complications in people with diabetes.

1 investor

ReviMo develops Niko, a mobility assistance device that helps individuals with limited mobility transfer, move, and elevate to a standing level, reducing dependence on caregivers. The device targets patients with limited mobility and their caregivers, and is subject to FDA approval.

1 investor

ReviMo develops Niko, a motorized mobility device that assists individuals with limited mobility in transfers and standing. The device is designed for personal use and rehabilitation, offering safety features and compatibility with standard furniture.

1 investor

Revolve develops a surgical robotics platform with 5mm wristed instruments and zero-footprint design for operating rooms, enabling digital surgery at costs comparable to laparoscopy. The system is designed for access across independent outpatient centers and large health networks.

1 investor

Rheo is developing an all-in-one device for continuous vitals-based patient monitoring, using algorithms and AI to predict patient outcomes and automate inpatient vital sign collection. It targets hospitals, serving doctors, nurses, administrators, and patients to improve care quality and reduce costs.

1 investor

Rheon Medical develops novel surgical devices to treat glaucoma, aiming to improve treatment efficacy and reduce post-operative complications for patients. The company is a spin-off from EPFL and combines engineering expertise with clinical guidance from ophthalmology specialists.

1 investor

RheumaFinder is an AI-powered application that analyzes CT images to detect structural bone lesions in the sacroiliac joints, intended to support radiologists in identifying patients with rheumatic disease. The software operates as a cloud-native add-on to existing PACS systems for opportunistic detection of joint damage in medical imaging studies.

1 investor

Rheumasense develops clinical diagnostic testing technology aimed at transforming the management and care of rheumatoid arthritis. The company is advancing its diagnostic platform toward FDA submission and commercialization.

1 investor

Rheyo manufactures a light-activated chairside whitening system for dental practices, distributed through a pilot program model where practices receive the device free and pay per-use for consumable kits.

1 investor

RhoDx develops cell-free DNA and RNA enrichment technologies for liquid biopsy cancer diagnostics. The company provides ultra-sensitive mutation detection methods to improve the performance and accessibility of liquid biopsy testing.

1 investor

Rhovica Neuroimaging AG develops a patented navigation system for safe placement of brain catheters in acute cerebral hemorrhage cases, enabling real-time monitoring and bedside treatment in emergency settings. The company serves hospitals and emergency care providers in the medical device and neurosurgery sector.

1 investor

Rhythmlink designs and manufactures medical devices and provides contract manufacturing services for neurodiagnostic equipment, serving healthcare providers and diagnostic centers. The company specializes in physical connections between patients and neurophysiologic recording equipment.

1 investor

RIGImmune is a biotechnology company developing stem loop RNA (SLR) therapeutics that activate the RIG-I innate immune sensor and the Type I interferon pathway for use against serious respiratory diseases. It operates a non-lipid-nanoparticle delivery platform called NEED (Nano-Emulsion Enhanced Delivery) for delivering RNA therapeutics directly to the respiratory tract.

1 investor

RIN Institute develops antibody-based pharmaceuticals and in vitro diagnostic drugs for medical research and clinical use. The company was spun out from Japan's National Cancer Center.

1 investor

Risk Sciences International is a boutique consulting firm specializing in risk assessment, management, and communication for organizations across private, public, and civil sectors. The firm serves multinational corporations, federal governments, multilateral organizations, and community-level clients addressing risks to health, infrastructure, environment, and regulatory compliance.

1 investor

RiskLick develops Protocol AI, an AI-powered software platform for designing and developing clinical trial protocols and study plans to accelerate drug development timelines. The platform serves pharmaceutical companies and clinical research organizations seeking to reduce time to market and improve protocol quality.

1 investor

Ritivel builds an AI-native platform that automates regulatory workflows and documentation for life sciences companies, helping accelerate the submission of therapies to patients.

1 investor

HRSoft is a provider of enterprise compensation management software that enables organizations to design, manage, and automate complex pay programs including merit, bonus, equity, and incentive plans. The platform integrates with leading HRIS systems and serves large enterprises navigating complex global compensation structures.

1 investor

River Biomedics develops human cardiac in vitro models used for drug target and compound validation, building a pipeline of cardiac therapies. It focuses on treatments for cardiac diseases by targeting biological processes involved in their pathology.

1 investor

River is developing a speech brain-computer interface (BCI) that operates without touching the brain, aimed at restoring and augmenting human communication. The company collaborates with academic and clinical research partners in neuroscience and neural engineering.

1 investor

RiverD designs and manufactures non-invasive skin analysis devices based on Raman spectroscopy technology for scientific research, clinical applications, and industrial use. The company's instruments provide precise insights into skin composition and topical product penetration.

1 investor